Table 1 Relationship between the eligibility criteria and clinicopathological features (n = 160).
From: Prognostic impact of clinical trial eligibility in patients with advanced gastric cancer
Factor | Eligibility criteria, n (%) | P value | ||
|---|---|---|---|---|
Total (n = 160) | Eligible group (n = 76) | Ineligible group (n = 84) | ||
Sex, male/female | 98 (61.3)/62 (38.8) | 50 (65.8)/26 (34.2) | 48 (57.1)/36 (42.9) | 0.33 |
Median age, years | 68 | 63 | 72 | < 0.01 |
Performance status, 0–1/2–3 | 116 (72.5)/44 (27.5) | 76 (100.0)/0 (0.0) | 40 (47.6)/44 (52.4) | < 0.01 |
Tumor location, whole–upper/middle–lower | 96 (60.0)/64 (40.0) | 46 (60.5)/30 (39.5) | 50 (59.5)/34 (40.5) | 1.00 |
Macroscopic type, type non–4/type 4 | 100 (62.5)/60 (37.5) | 47 (61.8)/29 (38.2) | 53 (63.1)/31 (36.9) | 0.87 |
Depth of tumor invasion, cT1–2/cT3–4 | 1 (0.6)/159 (99.4) | 1 (1.3)/75 (98.7) | 0 (0.0)/84 (100.0) | 0.48 |
Lymph node metastasis, cN0–1/cN2–3 | 61 (38.1)/99 (61.9) | 29 (38.2)/47 (61.8) | 32 (38.1)/52 (61.9) | 1.00 |
Number of distant metastatic sites, 1/≥ 2 | 116 (72.5)/44 (27.5) | 54 (71.1)/22 (29.0) | 62 (73.8)/22 (26.2) | 0.73 |
Liver metastasis, presence | 34 (21.3) | 18 (23.7) | 16 (19.1) | 0.56 |
Lung metastasis, presence | 3 (1.9) | 3 (4.0) | 0 (0.0) | 0.10 |
Distant lymph node metastasis, presence | 46 (28.8) | 24 (31.6) | 22 (26.2) | 0.49 |
Peritoneal dissemination, presence | 107 (66.9) | 46 (60.5) | 61 (72.6) | 0.13 |
Bone metastasis, presence | 4 (2.5) | 0 (0.0) | 4 (4.8) | 0.12 |
Histological type, differentiated/undifferentiated | 36 (22.5)/124 (77.5) | 17 (22.4)/59 (77.6) | 19 (22.6)/65 (77.4) | 1.00 |
First-line regimen of chemotherapy, S-1 alone/taxane-based or platinum-based | 3 (1.9)/157 (98.1) | 0 (0.0)/76 (100.0) | 3 (3.6)/81 (96.4) | 0.25 |
Dose reduction in the first-line chemotherapy initiation, presence | 60 (37.5) | 22 (28.9) | 38 (45.2) | 0.04 |
Median number of administrations in the first-line chemotherapy | 4 | 5 | 3 | < 0.01 |
Treatment-related adverse events (any grade), presence | 142 (88.8) | 67 (88.2) | 75 (89.3) | 1.00 |
Conversion surgery, presence | 44 (27.5) | 29 (38.2) | 15 (17.9) | < 0.01 |
